Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02987543
Recruitment Status : Active, not recruiting
First Posted : December 9, 2016
Last Update Posted : April 21, 2020
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
Foundation Medicine, Inc.
Myriad Genetics, Inc.
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 4, 2019
Estimated Study Completion Date : February 5, 2021